Health Technology · Pharmaceuticals: Major · NSE: MARKSANS · data 2026-10-09

Marksans Pharma Limited

Health check: Strong (8.5/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹309.1

Market cap

₹13,953 cr

P/E

27.1

P/B

—

ROE

15.2%

ROCE

16.3%

Debt / equity

0.11

Dividend yield

0.29%

1-year return

86.2%

52-week high

₹350.95

52-week low

₹155

Operating margin

19.3%

Growth

Revenue (last 12 months)	₹3,172 cr
Net profit (last 12 months)	₹517 cr
Sales growth, 3 years (yearly)	16.7%
Profit growth, 3 years (yearly)	16.2%

Chart patterns

Double top — forming (key level ₹301.1)

Similar companies

NATCO Pharma Limited (NATCOPHARM) · Jubilant Pharmova Limited (JUBLPHARMA) · AstraZeneca Pharma India Limited (ASTRAZEN) · Indegene Limited (INDGN) · Anupam Rasayan India Ltd. (ANURAS)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open MARKSANS in NSE Scanner →